Understanding the Myasthenia Gravis Study Results

Objective

This study aimed to understand how well the Myasthenia Gravis (MG) Symptoms Patient-Reported Outcome (PRO) scale relates to other measures of daily living and muscle strength in patients with MG. We used data from a clinical trial called MycarinG.

Background

The MG Symptoms PRO is a new tool that looks at five different areas of MG symptoms:

Muscle Weakness Fatigability
Physical Fatigue
Bulbar Muscle Weakness (affecting speaking and swallowing)
Ocular Muscle Weakness (affecting eye movement)
Respiratory Muscle Weakness

Study Design

In the MycarinG study, patients received either a medication called rozanolixizumab or a placebo for six weeks. We compared changes in daily functioning and muscle strength to the scores from the MG Symptoms PRO scale.

Main Findings

In total, 200 patients participated in the study.
Strong correlations were found between:
- Ocular Muscle Weakness and its related daily living score (0.78)
- Bulbar Muscle Weakness and its related score (0.72)
Moderate correlations were observed for:
- Respiratory Muscle Weakness (0.58)
- Physical Fatigue with limb weakness (0.60)
- Muscle Weakness Fatigability with bulbar weakness (0.52)
Most relationships with QMG scores (another measurement tool) were weak, suggesting differences in patient-reported and clinician-reported measures.

Conclusions

The MG Symptoms PRO scale is helpful in evaluating patients’ experiences with MG and correlates better with daily living tasks than with clinician evaluations. This tool can enhance our understanding of MG symptoms and assist in measuring treatment impacts more accurately.